Furthermore, the administration of DENA/AAF elevated MCP-1 levels compared with that in normal controls; these results agreed with those of Pan et al. [54], who proposed that MCP-1 dramatically improved lung cancer detection sensitivity; this biomarker arrangement may be useful for early lung cancer diagnosis, therapy, and prognosis. Here, CCL2 is linked to lung cancer.